ADPKD
MCID: ATS347
MIFTS: 62

Autosomal Dominant Polycystic Kidney Disease (ADPKD) malady

Categories: Genetic diseases, Rare diseases, Nephrological diseases

Aliases & Classifications for Autosomal Dominant Polycystic Kidney Disease

About this section

Aliases & Descriptions for Autosomal Dominant Polycystic Kidney Disease:

Name: Autosomal Dominant Polycystic Kidney Disease 11 48 13
Adpkd 23 48 24 50
Polycystic Kidney Disease, Autosomal Dominant 23 24 27
Polycystic Kidney Diseases 39 68
Polycystic Kidney and Hepatic Disease 1 11
 
Polycystic Kidney Disease, Adult Type 48
Polycystic Kidney, Autosomal Dominant 68
Polycystic Kidney Disease Adult 27
Congenital Biliary Ectasias 11
Polycystic Kidney Disease 13

Characteristics:

GeneReviews:

23
Penetrance: cyst development. penetrance of adpkd is very high: practically all older adults with a pkd1 or pkd2 pathogenic variant develop multiple bilateral cysts. because the disease is progressive, few cysts may be evident during childhood or young adulthood, especially in individuals with pkd2...


Classifications:



External Ids:

Disease Ontology11 DOID:898
ICD1030 Q61.3
ICD9CM32 753.12
MeSH39 D007690
NCIt45 C75464

Summaries for Autosomal Dominant Polycystic Kidney Disease

About this section
NIH Rare Diseases:48 Autosomal dominant polycystic kidney disease (adpkd) is a genetic disorder characterized by the growth of numerous cysts in the kidneys. it is the most common inherited disorder of the kidneys. symptoms usually develop between the ages of 30 and 40, but they can begin earlier, even in childhood. the most common symptoms are pain in the back and the sides and headaches. other symptoms include liver and pancreatic cysts, urinary tract infections, abnormal heart valves, high blood pressure, kidney stones, brain aneurysms, and diverticulosis. about 90 percent of all cases of polycystic kidney disease (pkd) are inherited in an autosomal dominant fashion. adpkd is caused by mutations in the pkd1 and pkd2 gene. although there is no cure for adpkd, treatment can ease symptoms and prolong life. last updated: 11/7/2016

MalaCards based summary: Autosomal Dominant Polycystic Kidney Disease, also known as ADPKD, is related to pyelonephritis and polycythemia. An important gene associated with Autosomal Dominant Polycystic Kidney Disease is PKD2 (Polycystin 2, Transient Receptor Potential Cation Channel), and among its related pathways are NO-dependent CFTR activation (normal and CF) and TP53 Regulates Metabolic Genes. Affiliated tissues include the kidney, kidney and liver, and related mouse phenotypes are Decreased cell migration and respiratory system.

Disease Ontology:11 An autosomal dominant disease characterized by the presence of multiple cysts located in the kidney resulting from ciliopathy that disrupts the function of primary cilium.

Wikipedia:71 Autosomal dominant polycystic kidney disease (ADPKD, autosomal dominant PKD or adult-onset PKD) is the... more...

GeneReviews for NBK1246

Related Diseases for Autosomal Dominant Polycystic Kidney Disease

About this section

Diseases in the Polycystic Kidney Disease family:

Polycystic Kidney Disease 2 Polycystic Kidney Disease, Adult Type I
Polycystic Kidney Disease 3 autosomal dominant polycystic kidney disease
Polycystic Kidney Disease 1, Autosomal Dominant Polycystic Kidney Disease 2, Autosomal Dominant

Diseases related to Autosomal Dominant Polycystic Kidney Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 152)
idRelated DiseaseScoreTop Affiliating Genes
1pyelonephritis30.4ACE, CFTR, NOS3, REN
2polycythemia30.0MTOR, TSC1, TSC2
3polycystic kidney disease 211.9
4polycystic kidney disease11.7
5polycystic kidney and hepatic disease11.6
6polycystic kidney disease, adult type i11.6
7polycystic liver disease11.3
8kidney disease11.3
9polycystic kidney disease, infantile severe, with tuberous sclerosis11.1
10glomerulocystic kidney disease with hyperuricemia and isosthenuria10.9
11caroli disease10.9
12polycystic kidney disease 310.9
13potter's syndrome10.9
14dengue hemorrhagic fever10.6
15chronic interstitial cystitis10.6
16aneurysm10.5
17hepatitis10.4
18endotheliitis10.4
19intracranial aneurysm10.4
20liver disease10.3
21spermatogenic failure 1010.3PKD1, TSC2
22chromosome 18p tetrasomy10.3PKD1, TSC2
23renal cell carcinoma10.3
24congenital hepatic fibrosis10.3
25hypotrichosis simplex10.3ACE, REN
26nephrolithiasis10.2
27iris disease10.2ACE, NOS3, REN
28hyperinsulinemic hypoglycemia, familial, 310.2ACE, REN
29lymphadenitis10.2ACE, NOS3, REN
30hemolytic anemia due to adenylate kinase deficiency10.2MTOR, TSC1
31myopia10.2ACE, AQP2, REN
32cascade stomach10.2ACE, PKHD1, REN
33pulmonary valve insufficiency10.2ACE, AQP2, REN
34aorta angiosarcoma10.2ACE, AQP2, REN
35cystic fibrosis10.2
36glomerulonephritis10.2
37peritonitis10.2
38pilocytic astrocytoma10.2MTOR, TSC1, TSC2
39capillary hemangioma10.2NOS3, PKHD1, REN
40pleomorphic xanthoastrocytoma10.2MTOR, TSC1, TSC2
41auricular cancer10.2MTOR, TSC1, TSC2
42gallbladder cancer10.1MTOR, TSC1, TSC2
43limb ischemia10.1ACE, NOS3, REN
44melorheostosis with osteopoikilosis10.1TSC1, TSC2
45gangliosidosis gm110.1MTOR, TSC1, TSC2
46carbohydrate metabolic disorder10.1ACE, REN
47diabetic encephalopathy10.1ACE, NOS3, REN
48atrophic vulva10.1PKDREJ, PKHD1, PRKD1
49marfan syndrome10.1
50tuberous sclerosis10.1

Graphical network of the top 20 diseases related to Autosomal Dominant Polycystic Kidney Disease:



Diseases related to autosomal dominant polycystic kidney disease

Symptoms & Phenotypes for Autosomal Dominant Polycystic Kidney Disease

About this section

GenomeRNAi Phenotypes related to Autosomal Dominant Polycystic Kidney Disease according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00055-A-19.8ENPP1, MTOR, PKD1, PKD2, TSC1

MGI Mouse Phenotypes related to Autosomal Dominant Polycystic Kidney Disease according to GeneCards Suite gene sharing:

41 (show all 17)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053889.0CFTR, MTOR, NOS3, PKD1, PKD2, PKHD1
2MP:00053758.8ACE, ENPP1, MTOR, MYC, NOS3, PKD1
3MP:00053818.8CFTR, EGF, MYC, NOS3, PKD1, PKD2
4MP:00053698.5ENPP1, MTOR, MYC, NOS3, PKD1, PRKD1
5MP:00028738.3CFTR, EGF, MTOR, MYC, NOS3, PKD1
6MP:00107718.2AQP2, EGF, ENPP1, MYC, PCSK2, PKD1
7MP:00053877.9ACE, CFTR, EGF, ENPP1, MTOR, MYC
8MP:00053867.8ACE, AQP2, CFTR, ENPP1, MTOR, MYC
9MP:00053977.8ACE, AQP2, CFTR, MTOR, MYC, NOS3
10MP:00053797.5ACE, CFTR, EGF, MTOR, MYC, NOS3
11MP:00053897.4ACE, AQP2, CFTR, EGF, MYC, NOS3
12MP:00053857.4ACE, ENPP1, MTOR, MYC, NOS3, PCSK2
13MP:00053677.3ACE, AQP2, ENPP1, MTOR, NOS3, PCSK2
14MP:00053787.2ACE, AQP2, CFTR, EGF, ENPP1, MTOR
15MP:00053707.2ACE, CFTR, ENPP1, MYC, NOS3, PKD1
16MP:00053766.9ACE, AQP2, CFTR, ENPP1, MTOR, MYC
17MP:00107686.5ACE, AQP2, CFTR, ENPP1, MTOR, MYC

Drugs & Therapeutics for Autosomal Dominant Polycystic Kidney Disease

About this section

Drugs for Autosomal Dominant Polycystic Kidney Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 131)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
CilnidipineapprovedPhase 4, Phase 28132203-70-45282138
Synonyms:
(+-)-(E)-Cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl (2E)-3-phenyl-2-propenyl ester
132203-70-4
2-methoxyethyl (2E)-3-phenylprop-2-en-1-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
3-O-(2-methoxyethyl) 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
AC-270
AC1NQZJB
Atelec
Atelec (TN)
BRD-A07875874-001-01-6
Bio-0164
C1493_SIGMA
C27H28N2O7
CHEBI:31399
CHEBI:438069
CHEMBL452076
CID5282138
 
Cilnidipine (JAN/INN)
Cilnidipine [INN]
Cinaldipine
Cinalong
D01173
FRC 8653
FRC-8653
HMS2089J07
I06-0491
LS-131293
MolPort-003-845-950
NCGC00162150-01
NCGC00162150-02
NCGC00162150-03
S1293_Selleck
STK623341
Siscard
cilnidipine
2
EverolimusapprovedPhase 4, Phase 2, Phase 3, Phase 11940159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
3
Sirolimusapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 1194053123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
4
CandesartanapprovedPhase 4, Phase 2157139481-59-72541
Synonyms:
139481-59-7
2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid
2-Ethoxy-1-(P-(O-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid
2-Ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid
2-Ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid
2-Ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4ethyl]}-1H-benzimidazole-7-carboxylic acid
2-Ethoxy-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl] methyl]-3H-benzoimidazole-4-carboxylic acid
2-ethoxy-1-({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl)-1H-benzimidazole-7-carboxylic acid
2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid
2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4ethyl}-1H-benzimidazole-7-carboxylic acid
2-ethoxy-3-[[4-[2-(1h-tetrazol-5-yl)phenyl]phenyl]methyl]-3h-benzoimidazole-4-carboxylic acid
2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
2-ethoxy-7-carboxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methylbenzimidazole
AC-203
AC1L1DWT
Amias
Atacand
Atacand, Blopress, Amias, Ratacand,Candesartan
BIDD:GT0350
Blopress
Blopress (TN)
C07468
C081643
C24H20N6O3
CHEBI:216848
 
CHEBI:3347
CHEMBL1016
CID2541
CV 11974
CV-11974
CV11974
Candesartan (USAN/INN)
Candesartan [BAN]
Candesartan [USAN:INN]
Candesartan cilexetil
D00522
DB00796
FT-0083585
HMS2089M22
HSDB 7520
I01-0374
KS-5003
L000156
LS-32740
MolPort-003-845-570
MolPort-005-943-739
NCGC00167474-01
Ratacand
S1578_Selleck
TL8000897
UNII-S8Q36MD2XX
candesartan
5
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 2, Phase 3, Phase 1370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
6Adrenergic AntagonistsPhase 41573
7Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 122062
8Antifungal AgentsPhase 4, Phase 2, Phase 3, Phase 13696
9Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 113086
10Adrenergic AgentsPhase 45352
11Angiotensin Receptor AntagonistsPhase 4, Phase 3, Phase 21191
12Adrenergic alpha-AntagonistsPhase 4739
13Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 17180
14Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 111226
15Antihypertensive AgentsPhase 4, Phase 3, Phase 24207
16AngiotensinogenPhase 4, Phase 3, Phase 21177
17Angiotensin-Converting Enzyme InhibitorsPhase 4, Phase 3, Phase 2724
18Calcium, DietaryPhase 4, Phase 3, Phase 25713
19calcium channel blockersPhase 4, Phase 3, Phase 21985
20
Angiotensin IIPhase 4, Phase 3, Phase 2117868521-88-0, 11128-99-765143, 172198
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
Ang II
Angiotensin 2
Angiotensin II (human)
 
Angiotensin II (mouse)
Angiotonin
Asp-arg-val-TYR-ile-his-pro-phe
Human angiotensin II
Hypertensin
Ile(5)-angiotensin II
21
Candesartan cilexetilPhase 4, Phase 2157145040-37-52540
Synonyms:
(+-)-1-Hydroxyethyl 2-ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylate, cyclohexyl carbonate (ester)
1-(cyclohexylocarbonyloxy)ethyl-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-1H-benzimidazole-7-carboxylate
1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate
145040-37-5
1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester
2-Ethoxy-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester
2-ethoxy-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-benzoimidazole-4-carboxylic acid 1-cyclohe
AC-204
AC1L1DWQ
ATACAND HCT
Almirall brand of candesartan cilexetil
Amias
Astra brand of candesartan cilexetil
AstraZeneca brand of candesartan cilexetil
Atacand
Atacand (TN)
BRD-A65671304-001-02-6
BSPBio_002691
C07709
C077793
C33H34N6O6
CHEBI:216349
CHEMBL1014
CID2540
Candesartan cilexetil
Candesartan cilexetil (JAN/USAN)
Candesartan cilexetil [USAN]
Candesartan hexetil
D00626
FT-0082579
H212/91
 
HMS1922J09
HMS2093E20
I06-0090
KBio2_002187
KBio2_004755
KBio2_007323
KBio3_001911
KBioGR_001607
KBioSS_002187
Kenzen
L006257
LS-32741
MolPort-003-666-552
NCGC00095123-01
NCGC00095123-02
NCGC00095123-03
Parapres
Promed brand of candesartan cilexetil
Racanda
SPBio_000349
SPECTRUM1504261
ST51052687
Spectrum2_000485
Spectrum3_000996
Spectrum4_001124
Spectrum5_001462
Spectrum_001707
TCV 116
TCV-116
TL8000995
Takeda brand of candesartan cilexetil
UNII-R85M2X0D68
candesartan cilexitil
22Angiotensin II Type 1 Receptor BlockersPhase 4, Phase 31091
23Peripheral Nervous System AgentsPhase 4, Phase 223689
24
CurcuminPhase 4146458-37-7969516
Synonyms:
1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione
1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione
C.I. Natural Yellow 3
CI Natural Yellow 3
Cucurmin
Curcuma
Curcumin
Curcumin I
Diferaloylmethane
Diferuloylmethane
Gelbwurz
Golden seal
Haidr
Halad
Haldar
Halud
Hydrastis
 
Indian saffron
Indian turmeric
Kacha haldi
Kurkumin [czech]
Merita earth
Natural yellow 3
Orange root
Safran D'inde
Souchet
Terra merita
Tumeric yellow
Turmeric
Turmeric (>98% curcurmin)
Turmeric oleoresin (79%-85% curcumin)
Turmeric yellow
Yellow ginger
Yellow puccoon
Yellow root
Yo-kin
Zlut prirodni 3 [Czech]
25Antirheumatic AgentsPhase 410956
26AnalgesicsPhase 411733
27Anti-Inflammatory Agents, Non-SteroidalPhase 44443
28Analgesics, Non-NarcoticPhase 46501
29Anti-Inflammatory AgentsPhase 410729
30
lanreotideapprovedPhase 2, Phase 386108736-35-2
Synonyms:
Lanreotide
 
Lanreotide acetate
Somatuline Depot
31
Lisinoprilapproved, investigationalPhase 311783915-83-75362119
Synonyms:
(2S)-1-[(2S)-6-amino-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]hexanoyl]pyrrolidine-2-carboxylic acid
(S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
(S)-1-(N(2)-(1-carboxy-3-phenylpropyl)-L-lysyl)-L-proline
(S)-1-(N(sup 2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
(S)-1-(N2-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
1-(N2-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
1-[Nalpha-[(S)-1-Carboxy-3-phenylpropyl]-L-lysyl]-L-proline
76547-98-3
77726-95-5
83915-83-7 (Parent)
AC1NSFPF
Acerbon
Acercomp
Alapril
BB_NC-1454
BIDD:GT0755
BPBio1_000290
BRD-K67966701-335-03-5
BRN 4276619
BSPBio_000262
C21H31N3O5
CCRIS 3568
CHEBI:43755
CHEMBL1237
CID5362119
Carace
Cipral
Cipril
Coric
D08131
DB00722
DivK1c_001037
Doneka
EINECS 278-488-1
HMS1921B14
HMS2090O14
HMS2092L21
HMS503O15
I06-1895
ICI-209K
IDI1_001037
Inhibril
Inopril
KBio1_001037
KBio2_000977
KBio2_003545
KBio2_006113
KBio3_002002
KBioGR_001599
KBioSS_000977
L0220
LPR
LS-118899
Linopril
Linvas
Lipril
Lisinal
 
Lisinopril
Lisinopril (INN)
Lisinopril (anhydrous)
Lisinopril Dihydrate
Lisinopril anhydrous
Lisinoprilum
Lisinoprilum [Latin]
Lisipril
Lisoril
Lispril
Longes
Loril
Lysinopril
MK 521
MK 522
MK-521
MLS001306436
MLS001306481
MolPort-002-507-428
N(2)-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline
N-(1(S)-Carboxy-3-phenylpropyl)-L-lysyl-L-proline
N2-((S)-1-Carboxy-3-phenylpropyl)-L-lysyl-L-proline
N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline
NCGC00179623-01
NINDS_001037
Noperten
Novatec
Presiten
Prestwick0_000301
Prestwick1_000301
Prestwick2_000301
Prestwick3_000301
Prinil
Prinivil
Prinzide
Renacor
SMR000544473
SPBio_001351
SPBio_002481
SPECTRUM1501217
Sinopril
Sinopryl
Spectrum2_001456
Spectrum3_000941
Spectrum4_001040
Spectrum5_000995
Spectrum_000497
TL8005499
Tensopril
Tensyn
Tersif
Vivatec
Zestoretic
Zestril
Zestril (TN)
[N2-[(S)-1-CARBOXY-3-PHENYLPROPYL]-L-LYSYL-L-PROLINE
[N2-[(S)-1-CARBOXY-3-phenylpropyl]-L-lysyl-L-proline
lisinopril
32
SomatostatinapprovedPhase 2, Phase 323738916-34-6, 51110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
33
TolvaptanapprovedPhase 3, Phase 290150683-30-0216237
Synonyms:
( -)-4'-((7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl)-o-tolu-m-toluidide
150683-30-0
7-Chloro-5-hydroxy-1-(2-methyl-4-(2-methylbenzoylamino)benzoyl)2,3,4,5-tetrahydro-1H-1-benzazepine
AC1L50C9
C116664
CHEBI:327437
CHEMBL344159
CID216237
 
L001628
N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide
OPC 41061
OPC-41061
PDSP1_001738
PDSP2_001721
Samsca
Tolvaptan
UNII-21G72T1950
benzazepine derivative, 32
34
Telmisartanapproved, investigationalPhase 3268144701-48-465999
Synonyms:
144701-48-4
2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid
4'-((1,4'-Dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid
4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid
4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid
4'-((4-mehtyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimmidazolyl)methyl)-2-biphenylcarboxylic acid
4'-[(1,4'-Dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid
4'-[(1,4'-dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid
4'-[(1,7'-Dimethyl-2'-propyl-1H,3'h-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid
4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl][1,1'-biphenyl]-2-carboxylic acid
4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid
AC-2013
AC1L24EB
AC1Q5U7O
Abbott brand of telmisartan
BAY-68-9291
BAY68-9291
BIBR 277
BIBR 277SE
BIBR-277
BIBR-277-SE
BIBR-277SE
BIDD:GT0365
BRD-K73999723-001-02-2
BSPBio_002738
Bay 68-9291
Bio-0103
Boehringer Ingelheim brand of telmisartan
C07710
C084178
C33H30N4O2
CHEBI:9434
CHEMBL1017
CID65999
CPD000466326
D00627
DB00966
Glaxo Wellcome brand of telmisartan
GlaxoSmithKline brand of telmisartan
 
HMS1922P07
HMS2051P16
HMS2090P17
HMS2093M22
HSDB 7590
I06-0281
KBio3_001958
KBioGR_001842
Kinzal
Kinzalmono
L001035
LS-44263
MLS000759432
MLS001076687
Micardis
Micardis (TN)
Micardis HCT
Micardis, Targit, Temax, BIBR277, Telmisartan
MolPort-003-666-621
NCGC00095150-01
NCGC00095150-02
NCGC00095150-03
Pritor
S1738_Selleck
SAM001246602
SMR000466326
SPBio_002131
SPECTRUM1505261
STK624049
Spectrum2_001976
Spectrum3_001089
Spectrum4_001261
Spectrum5_001053
TL8000991
Telmisartan
Telmisartan (JAN/USAN/INN)
Telmisartan [USAN:INN]
UNII-U5SYW473RQ
YM-086
telmisartan
35
Octreotideapproved, investigationalPhase 3, Phase 222383150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
 
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
36
DiltiazemapprovedPhase 37742399-41-739186
Synonyms:
(+)-cis-5-[2-(dimethylamino)Ethyl]-2,3-dihydro-3-hydroxy-2-(P-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester
(+)-cis-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester
(2S,3S)-5-(2-(dimethylamino)Ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate
(2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate
(2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate
(2S,3S)-5-[2-(dimethylamino)ethyl]-2-[4-(methyloxy)phenyl]-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate
(2S-cis)-3-(Acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one
(2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one
144604-00-2
33286-22-5
42399-41-7
AC-936
AC1L2181
AC1Q6LHX
Acalix
Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester
Adizem
Aldizem
Altiazem
Anginyl
Angizem
Anoheal
Apo-Diltiaz
BIDD:GT0548
BPBio1_000230
BRD-K24023109-001-02-5
BRD-K24023109-003-03-9
BRN 3573079
BSPBio_000208
BSPBio_001311
Bio1_000371
Bio1_000860
Bio1_001349
Britiazim
Bruzem
C06958
C22H26N2O4S
CHEBI:101278
CHEMBL23
CID39186
Calcicard
Cardil
Cardizem
Cardizem (Hydrochloride)
Cardizem CD
Cardizem SR
Cardizen LA
Cartia XT
Citizem
Cormax
D-cis-Diltiazem
D07845
DB00343
Deltazen
Dilacor
Dilacor-XR
Diladel
Dilcontin
 
Dilpral
Dilren
Dilrene
Dilt-cd
Dilta-Hexal
Diltia
Diltiazem
Diltiazem (INN)
Diltiazem [INN:BAN]
Diltiazemum
Diltiazemum [INN-Latin]
Dilticard
Diltzac
Dilzem
Dilzen
EINECS 255-796-4
Endrydil
FT-0081415
HMS1791B13
HMS1989B13
HMS2089H09
HSDB 6528
Herbesser
Incoril AP
LS-40510
Lopac0_000327
MK-793 (Malate)
Masdil
MolPort-002-509-369
NCGC00024309-02
NCGC00024309-04
NCGC00024309-05
NCGC00024309-06
NCGC00024309-07
NCGC00024309-08
NCGC00024309-09
NCGC00024309-10
Novo-Diltazem
Nu-Diltiaz
Prestwick0_000134
Prestwick1_000134
Prestwick2_000134
Prestwick3_000134
RG 83606 (Hydrochloride)
SPBio_002147
STOCK1N-03672
Surazem (TN)
Syn-Diltiazem
Tiamate
Tiazac
Tiazac Tildiem
Tiazac XC
Tocris-0685
UNII-EE92BBP03H
Viazem
[(2S,3S)-5-(2-dimethylaminoethyl)-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate
d-cis-Diltiazem
diltiazem
nchembio.368-comp1
37
MinoxidilapprovedPhase 33438304-91-54201
Synonyms:
16317-69-4
2,3-Dihydro-3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine
2,4-Diamino-6-piperidinilpirimidina-3-ossido
2,4-Diamino-6-piperidinilpirimidina-3-ossido [Italian]
2,4-Diamino-6-piperidino-pyrimidine-3-oxide
2,4-Diamino-6-piperidinopyrimidine 3-N-oxide
2,4-Diamino-6-piperidinopyrimidine 3-oxide
2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide
2,6-Diamino-4-piperidinopyrimidin-1-oxid
3-hydroxy-2-imino-6-(1-piperidyl)pyrimidin-4-amine
3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine
38304-91-5
5-25-12-00317 (Beilstein Handbook Reference)
6-(1-Piperidinyl)-2,4-pyrimidinediamine 3-oxide
6-(piperidin-1-yl)pyrimidine-2,4-diamine 3-oxide
6-Amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine
6-Piperidin-1-ylpyrimidine-2,4-diamine 3-oxide
6-Piperidino-2,4-diaminopyrimidine 3-oxide
6-[1-Piperidinyl]pyrimidine-2,4-diamine 3 oxide
AB00513797
AC-5271
AC1L1HN1
Alopexil
Alostil
Ambap38304-91-5
Apo-Gain
Apo-gain
BCBcMAP01_000193
BPBio1_000065
BRD-K06902185-001-05-2
BRD-K14888893-001-02-3
BRN 0886240
BSPBio_000059
BSPBio_001385
BSPBio_002037
Bio1_000084
Bio1_000573
Bio1_001062
Bio2_000105
Bio2_000585
C9H15N5.H2O
CAS-38304-91-5
CBiol_001798
CHEBI:49774
CHEBI:6942
CHEMBL609587
CHEMBL802
CID4201
CPD-7668
CPD000058963
D00418
D008914
DB00350
DB08225
DivK1c_000160
EINECS 253-874-2
EU-0100786
Gen-Minoxidil
HMS1361F07
HMS1568C21
HMS1791F07
HMS1920P03
HMS1989F07
HMS2089L08
HMS2091F20
HMS500H22
HSDB 6538
IDI1_000160
IDI1_033855
Jsp006715
KBio1_000160
KBio2_000105
KBio2_001449
KBio2_002673
KBio2_004017
KBio2_005241
KBio2_006585
KBio3_000209
KBio3_000210
KBio3_001537
KBioGR_000105
KBioGR_000585
KBioSS_000105
KBioSS_001449
LS-135040
Loniten
Loniten (TN)
Lonolox
Lopac-M-4145
 
Lopac0_000786
M 4145
M1389
MINOXIDIL (FOR MEN)
MINOXIDIL (FOR WOMEN)
MINOXIDIL EXTRA STRENGTH (FOR MEN)
MINOXIDIL EXTRA STRENGTH FOR MEN
MLS000028566
MLS000859953
MLS001077294
Men s Rogaine Foam
Men's Rogaine
Mens Rogaine Foam
Minodyl
Minossidile
Minossidile [Italian]
Minoxidil
Minoxidil (USP/INN)
Minoxidil Pfizer Brand
Minoxidil [USAN:BAN:INN]
Minoxidilum
Minoxidilum [INN-Latin]
Minoxigaine
Minoximen
MolPort-003-666-236
MolPort-005-932-694
NCGC00015673-01
NCGC00015673-02
NCGC00015673-04
NCGC00015673-11
NCGC00018278-01
NCGC00024666-01
NCGC00024666-02
NCGC00024666-03
NCGC00024666-04
NCGC00024666-05
NCGC00024666-06
NCGC00024666-07
NCGC00024666-08
NCGC00179672-01
NINDS_000160
Neoxidil
Normoxidil
Pfizer Brand of Minoxidil
Pierminox
Prestwick0_000020
Prestwick1_000020
Prestwick2_000020
Prestwick3_000020
Prestwick_521
Prexidil
Pyrimidine, 2,4-diamino-6-piperidino-, 3-oxide
ROGAINE (FOR MEN)
ROGAINE (FOR WOMEN)
ROGAINE EXTRA STRENGTH (FOR MEN)
Regaine
RiUP
Riup (TN)
Rogaine
Rogaine (TN)
Rogaine Extra Strength for Men
Rogaine for Men
Rogaine for Women
Rogaine, Regaine, Avacor and Mintop, Minoxidil
S1383_Selleck
SAM002589949
SBB056986
SGCUT00112
SMP1_000192
SMR000058963
SMR000326812
SPBio_001006
SPBio_001980
SPECTRUM1500415
Spectrum2_001053
Spectrum3_000509
Spectrum4_000063
Spectrum5_001299
Spectrum_000969
TM-160
Theroxidil
Tocris-0583
Tricoxidil
Trocoxidil
U 10858
U-10,858
U-10858
ZINC00001735
minoxidil
nchembio.79-comp10
to_000070
38
Metoprololapproved, investigationalPhase 321237350-58-6, 51384-51-14171
Synonyms:
(+/-)-Metoprolol
(RS)-Metoprolol
1-(Isopropylamino)-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol
1-(Isopropylamino)-3-(p-(2-methoxyethyl)phenoxy)-2-propanol
1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol
1-[(1-methylethyl)amino]-3-({4-[2-(methyloxy)ethyl]phenyl}oxy)propan-2-ol
1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol
1-[4-(2-methoxyethyl)phenoxy]-3-propan-2-ylamino-propan-2-ol
3-[4-(2-methoxyethyl)phenoxy]-1-(propan-2-ylamino)propan-2-ol
37350-58-6
51384-51-1
54163-88-1
AB00053499
AC-19022
AC1L1HKM
AstraZeneca Brand of Metaoprolol Tartrate
AstraZeneca Brand of Seloken
BRD-A03623303-045-02-0
Beatrolol
Beloc
Beloc Duriles
Beloc-Duriles
BelocDuriles
Betaloc
Betaloc Astra
Betaloc-Astra
BetalocAstra
Betalok
C07202
CCRIS 4198
CGP 2175
CGP-2175
CGP2175
CHEBI:6904
CHEMBL13
CID4171
D008790
D02358
DB00264
DL-metoprolol
Dl-Metoprolol
Dutoprol
EINECS 253-483-7
EINECS 257-166-4
H 93 26
H 93-26
H 9326
 
HMS2090B15
HSDB 6531
I01-7125
I06-0125
Jsp006606
L000669
LOPRESSIDONE
LS-122450
Leiras Brand of Metoprolol Succinate or Metoprolol Tartrate
Lopresor
Lopresoretic
Lopressor
Lopressor HCT
Meijoprolol
Metohexal
Metoprolol
Metoprolol (USAN/INN)
Metoprolol Tartrate
Metoprolol [USAN:INN:BAN]
Metoprolol slow release
Metoprolol succinate
Metoprolol tartrate
Metoprololum
Metoprololum [INN-Latin]
Metroprolol
MolPort-005-938-039
NCGC00021148-02
NCGC00021148-03
NCGC00021148-04
Novartis Brand of Metprolol Tartrate
Preblok
Prelis
Presolol
Selo-Zok
Seloken
Seloken AstraZeneca Brand
Selopral
Seroken
Spesicor
Spesikor
TOPROL-XL
Tartrate, Metoprolol
Toprol
Toprol XL
Toprol-XL
UNII-GEB06NHM23
dl-Metoprolol
metoprolol
39
Hydrochlorothiazideapproved, vet_approvedPhase 341358-93-53639
Synonyms:
125727-50-6
3,4-Dihydro-6-chloro-7-sulfamyl-1,2, 4-benzothi
3,4-Dihydrochlorothiazide
58-93-5
6-Chloro-7-sulfamoyl-3, 4-dihy
8049-49-8
AB00052012
AC-11072
AC1L1GDT
AC1Q55FM
AF-614/30832002
AKOS000121373
ARONIS24316
Acesistem
Acuilix
Acuretic
Aldactazide
Aldactazide 25/25
Aldazida
Aldectazide 50/50
Aldoril
Ambap58-93-5
Apo-Hydro
Apresazide
Aquarills
Aquarius
Aquazide H
Aquazide-H
BAS 00371709
BIDD:GT0153
BPBio1_000019
BRD-K13078532-001-05-2
BRN 0625101
BSPBio_000017
BSPBio_002132
Bio-0714
Bremil
Briazide
C7H8ClN3O4S2
CAS-58-93-5
CCRIS 2082
CHEMBL435
CID3639
CPD000035778
Caplaril
Capozide
Carozide
Catiazida
Chlorizide
Chlorosulthiadil
Chlorothiazide
Chlorsulfonamidodihydrobenzothiadiazine dioxide
Chlorzide
Chlothia
Cidrex
Clorana
Component of Butizide Prestabs
Concor Plus
Condiuren
D00340
D006852
DB00999
Diaqua
Dichlorosal
Dichlorotride
Dichlothiazide
Dichlotiazid
Dichlotride
Diclotride
Dicyclotride
Didral
Dihydran
Dihydrochlorothiazid
Dihydrochlorothiazide
Dihydrochlorothiazidum
Dihydrochlorurit
Dihydrochlorurite
Dihydroxychlorothiazidum
Direma
Disalunil
Disothiazid
Diu 25 Vigt
Diu-Melusin
Diu-melusin
Diuril
Diurogen
DivK1c_000289
Dixidrasi
Drenol
Dyazide
EINECS 200-403-3
EU-0100614
Esidrex
Esidrix
Esidrix (TN)
Esimil
Esoidrina
FT-0082750
Fluvin
H 4759
H1274
H2910_SIAL
H4759_SIAL
HCT
HCT-Isis
HCTZ
HCZ
HMS1568A19
HMS1920D19
HMS2091L05
HMS500O11
HMS553N04
HSDB 3096
Hidril
Hidro-Niagrin
Hidrochlortiazid
Hidroclorotiazida
Hidroclorotiazida [INN-Spanish]
Hidroronol
Hidrosaluretil
Hidrotiazida
Hyclosid
Hydrex-semi
Hydril
Hydro Par
Hydro-Aquil
Hydro-D
Hydro-Diuril
Hydro-Saluric
Hydro-T
Hydro-chlor
HydroDIURIL
Hydrochlorat
Hydrochloro Thiazide
Hydrochlorot
Hydrochlorothiazid
Hydrochlorothiazide
Hydrochlorothiazide (JP15/USP/INN)
Hydrochlorothiazide Intensol
Hydrochlorothiazide [INN:BAN:JAN]
 
Hydrochlorothiazidum
Hydrochlorothiazidum [INN-Latin]
Hydrochlorthiazide
Hydrochlorthiazidum
Hydrocot
Hydrodiuretic
Hydrodiuril
Hydropres
Hydrosaluric
Hydrothide
Hydrozide
Hydrozide Injection, Veterinary
Hypothiazid
Hypothiazide
Hytrid
Hyzaar
I09-0531
IDI1_000289
Idroclorotiazide
Idroclorotiazide [DCIT]
Idrotiazide
Inderide
Inderide 80/25
Indroclor
Ivaugan
Jen-Diril
KBio1_000289
KBio2_001357
KBio2_003925
KBio2_006493
KBio3_001352
KBioGR_000351
KBioSS_001357
LS-243
Lopac-H-4759
Lopac0_000614
Lopressor HCT
Lotensin HCT
Lotensin Hct
MLS000069619
Manuril
Maschitt
Maxzide
Maybridge Compound 10
Maybridge1_004336
Mazide 25 mg
Medozide
Megadiuril
Microzide
Microzide (TN)
Mictrin
Mikorten
Modurcen
Moduretic
MolPort-000-144-465
NCGC00015508-01
NCGC00015508-02
NCGC00015508-03
NCGC00015508-07
NCGC00015508-12
NCGC00021906-03
NCGC00021906-04
NCGC00021906-05
NCGC00021906-06
NCGC00021906-07
NCGC00021906-08
NCI-C55925
NCI60_004317
NINDS_000289
NSC 53477
NSC53477
Natrinax
Nefrix
Nefrol
Neo-Codema
Neo-Flumen
Neo-Minzil
Neo-codema
Neoflumen
Newtolide
Novodiurex
Oprea1_357174
Oretic
Pantemon
Panurin
Prestwick0_000009
Prestwick1_000009
Prestwick2_000009
Prestwick3_000009
Prestwick_263
Prinzide
Raunova Plus
Ro-Hydrazide
Ro-hydrazide
Roxane
S1708_Selleck
SAM002554901
SMR000035778
SPBio_001259
SPBio_001938
SPECTRUM1500335
STK315354
Saldiuril
Sectrazide
Selozide
Ser-Ap-Es
Servithiazid
Spectrum2_001040
Spectrum3_000456
Spectrum4_000006
Spectrum5_000824
Spectrum_000877
Spironazide
Su 5879
Tandiur
Thiaretic
Thiuretic
Thlaretic
Timolide
UNII-0J48LPH2TH
Unazid
Unipres
Urodiazin
Urozide
Vaseretic
Vetidrex
WLN: T66 BSWM EM DHJ HG ISZW
ZINC00896569
Ziac
Zide
adiazine-1,1-dioxide
component of Aldactazide
component of Aldoril
component of Caplaril
component of Cyclex
component of Dyazide
component of Esimil
diclot ride
dro-2H-1,2,4-benzothiadiazine 1,1-dioxide
hydrochlorothiazide
panurin dichloride
40
PravastatinapprovedPhase 315081093-37-054687
Synonyms:
(+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid
(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid
(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid
3beta-Hydroxycompactin
81093-37-0
81131-70-6 (hydrochloride salt)
AC1L1HJL
AC1Q5T3M
BIDD:GT0773
BRD-K60511616-236-01-4
C01844
C23H36O7
CCRIS 7557
CHEMBL1144
CID54687
Compactin
D08410
DB00175
Elisor
Eptastatin
FT-0082682
KS-5015
LS-94713
Lipostat
Mevalothin
Mevalotin
Mevastatin
Mevinolin
 
Oliprevin
Pravachol
Pravaselect
Pravastatin (INN)
Pravastatin Sodium
Pravastatin Sodium Salt
Pravastatin [INN:BAN]
Pravastatin acid
Pravastatin sodium
Pravastatin tert-Octylamine Salt
Pravastatina
Pravastatina [Spanish]
Pravastatine
Pravastatine [French]
Pravastatinum
Pravastatinum [Latin]
Pravator
Pravator (TN)
RMS-431
SQ-31,000
Selectin
Selektine
Selipran
UNII-KXO2KT9N0G
Vasten
nchembio.301-comp7
nchembio790-comp15
pravastatin
pravastatina
pravastatine
pravastatinum
41
ClonidineapprovedPhase 32404205-90-72803
Synonyms:
1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro- (9CI)
2,6-Dichloro-N-2-imidazolidinylidenebenzenamine
2,6-dichloro-N-(2-imidazolidinylidene)aniline
2,6-dichloro-N-2-imidazolidinylidenebenzenamide
2,6-dichloro-N-imidazolidin-2-ylideneaniline
2-((2,6-Dichlorophenyl)imino)imidazolidine
2-(2,6-Dichloroanilino)-1,3-diazacyclopentene-(2)
2-(2,6-Dichloroanilino)-2-imidazoline
2-(2,6-Dichlorophenylamino)-2-imidazoline
2-(2,6-Dichlorophenylimino)imidazolidine
2-Imidazoline, 2-(2,6-dichloroanilino)- (7CI,8CI)
2-[(2,6-Dichlorophenyl)imino]imidazoline
2-[(2,6-dichlorophenyl)imino]-2-imidazoline
4205-90-7
4205-91-8 (mono-hydrochloride)
57066-25-8
734571A
AB00514634
AC1L1EI5
AC1Q3K6V
AKOS001595470
Adesipress
BIDD:GT0547
BPBio1_000040
BRD-K98530306-001-02-1
BRD-K98530306-003-05-0
BSPBio_000036
BSPBio_001588
BSPBio_002055
Bio1_000470
Bio1_000959
Bio1_001448
Bio2_000308
Bio2_000788
C9H9Cl2N3
CAS-4205-91-8
CATAPRES-TTS-1
CATAPRES-TTS-2
CATAPRES-TTS-3
CCRIS 7787
CHEBI:3757
CHEBI:46632
CHEMBL134
CID2803
Catapres
Catapres- TTS
Catapres-TTS
Catapresan
Catapressan
Catarpres
Catarpres-TTS
Catarpres-TTS (TN)
Catarpresan
Chlofazoline
Chlornidinum
Clofenil
Clonidin
Clonidina
Clonidina [INN-Spanish]
Clonidine (JAN/USAN/INN)
Clonidine HCl
Clonidine [USAN:BAN:INN]
Clonidinhydrochlorid
Clonidinum
Clonidinum [INN-Latin]
Clonistada
Clopheline
D00281
DB00575
DB07566
DivK1c_000774
 
Dixarit
Duraclon
Duraclont
EINECS 224-119-4
Gemiton
HMS1361P10
HMS1791P10
HMS1989P10
HMS2089G11
HSDB 3040
Hemiton
IDI1_000774
IDI1_034058
Ipotensium
Isoglaucon
KBio1_000774
KBio2_000308
KBio2_001821
KBio2_002876
KBio2_004389
KBio2_005444
KBio2_006957
KBio3_000615
KBio3_000616
KBio3_001275
KBioGR_000308
KBioGR_001572
KBioSS_000308
KBioSS_001821
Klofelin
Klofenil
L000193
LS-79606
Lopac-C-7897
Lopac0_000268
M 5041T
M-5041T
MolPort-001-779-668
MolPort-005-932-374
N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine
NCGC00015268-01
NCGC00015268-02
NCGC00015268-08
NCGC00024734-01
NCGC00024734-02
NCGC00024734-03
NCGC00024734-04
NCGC00024734-05
NCGC00179680-01
NINDS_000774
Prestwick0_000248
Prestwick1_000248
Prestwick2_000248
Prestwick3_000248
SKF 34427
SPBio_001233
SPBio_002255
ST 155BS
ST-155-BS
ST-155BS
Spectrum2_001187
Spectrum3_000358
Spectrum4_000956
Spectrum5_000759
Spectrum_001341
T171
Tenso-Timelets
Tocris-0690
UNII-MN3L5RMN02
ZINC00896484
clonidine
nchembio.79-comp11
nchembio705-10
42
HydralazineapprovedPhase 34586-54-43637
Synonyms:
(1Z)-1(2H)-Phthalazinone hydrazone
(2H)-Phthalazinone hydrazone
1(2H)-Phthalazinone hydrazone
1(2H)-Phthalazinone, hydrazone
1-Hydrazinophthalazine
1-Phthalazinylhydrazine
304-20-1 (mono-hydrochloride)
5-25-17-00412 (Beilstein Handbook Reference)
6-Hydralazine
86-54-4
AC1L1GDN
AC1Q4UY1
AKOS000122609
Apresolin
Apresoline
Apressin
Apressin (pharmaceutical)
Apressoline
Aprezolin
BA 5968
BRD-K82103381-003-03-7
BRN 0132615
BSPBio_002130
C 5968
C-5068
C-5968
C07040
C8H8N4
CAS-304-20-1
CCRIS 5385
CHEBI:5775
CHEMBL276832
CID3637
Ciba 5968
D08044
DB01275
DivK1c_000117
EC-000.1838
EINECS 201-680-3
HLZ
Hidral
Hidral (TN)
Hidralazin
Hidralazina
Hidralazina [INN-Spanish]
Hidralazina [Spanish]
Hipoftalin
Hydralazin
Hydralazine (INN)
Hydralazine [INN:BAN]
Hydralazine hydrochloride
 
Hydralazinum
Hydralazinum [INN-Latin]
Hydrallazin
Hydrallazine
Hydrazinophthalazine
Hydrazone 1(2H)-phthalazinone
Hypophthalin
IDI1_000117
Idralazina
Idralazina [DCIT]
Idralazina [Italian]
InChI=1/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12)
KBio1_000117
KBio2_001355
KBio2_003923
KBio2_006491
KBio3_001350
KBioGR_000349
KBioSS_001355
LS-109171
Lopac-H-1753
Lopac0_000593
MolPort-000-876-738
MolPort-001-794-088
NCGC00015501-01
NCGC00015501-02
NCGC00015501-05
NCGC00162199-01
NCIOpen2_001484
NINDS_000117
NSC 126699
NSC126699
Oprea1_207681
Oprea1_416878
Phthalazin-1-ylhydrazine
Praparat 5968
Prestwick0_000169
Prestwick1_000169
Prestwick2_000169
SPBio_000977
SPBio_001958
ST50512087
Spectrum2_000969
Spectrum3_000455
Spectrum4_000005
Spectrum5_000822
Spectrum_000875
UNII-26NAK24LS8
WLN: T66 CNNJ BMZ
ZINC12360535
[2H-Phthalazin-(1Z)-Ylidene]-Hydrazine Hydrochloride
hydralazine
phthalazin-1-ylhydrazine
43
BenzocaineapprovedPhase 2, Phase 320161994-09-7, 94-09-72337
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
4-amino-benzoic acid ethyl ester
4-aminobenzoic acid ethyl ester
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
AE-562/40377256
AI3-02081
AKOS000119763
AR-1H9065
Acetate, Benzocaine
Aethoform
Aethylium paraminobenzoicum
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
BB_SC-0019
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
Baby Anbesol
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
Benzocaine
Benzocaine (USP/INN)
Benzocaine Acetate
Benzocaine Formate
Benzocaine Hydrobromide
Benzocaine Hydrochloride
Benzocaine Methanesulfonate
Benzocaine [INN:BAN]
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
C07527
CAS-94-09-7
CHEBI:116735
CHEMBL278172
CID2337
Caswell No. 430A
Chloraseptic
D001566
D00552
DB01086
Dermoplast
Diet Ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
ETHYL-P-AMINOBENZOATE
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl Aminobenzoate
Ethyl PABA
 
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
Formate, Benzocaine
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, Benzocaine
Hydrochloride, Benzocaine
I05-0204
IDI1_000932
Identhesin
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
MLS001331704
MLS002153970
Methanesulfonate, Benzocaine
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
NINDS_000932
NSC 122792
NSC 41531
NSC41531
NSC4688
Norcain
Norcaine
Norcainum
Oprea1_750694
Oprea1_827402
Ora-jel
Orabase-B
Orthesin
Otocain
Outgro
Parathesin
Parathesin (TN)
Parathesine
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Prestwick_991
SMR000059025
SPBio_000134
SPBio_002844
SPECTRUM1500139
STK043620
Slim Mint Gum
Solarcaine
Solu H
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
Spectrum_000074
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
benzocaine
ethylaminobenzoate-4
h-4-abz-oet
nchembio.182-comp4
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline
p-Ethoxycarboxylic aniline
44tannic acidapproved, NutraceuticalPhase 2, Phase 32016
45TriptolidePhase 3738748-32-2
46Contraceptive Agents, MalePhase 3233
47Liver ExtractsPhase 2, Phase 34067
48AngiopeptinPhase 2, Phase 386
49Contraceptive AgentsPhase 31967
50HIV Protease InhibitorsPhase 3, Phase 25470

Interventional clinical trials:

(show top 50)    (show all 91)
idNameStatusNCT IDPhase
1CCB Safety Study in Treatment of Hypertension of ADPKDUnknown statusNCT00541853Phase 4
2Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT00414440Phase 4
3Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKDRecruitingNCT02494141Phase 4
4Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)Unknown statusNCT02115659Phase 3
5Sirolimus for Massive Polycystic LiverUnknown statusNCT01680250Phase 2, Phase 3
6Open-Label Extension of LOCKCYST TrialUnknown statusNCT00771888Phase 2, Phase 3
7Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00346918Phase 3
8Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00456365Phase 3
9A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]CompletedNCT01022424Phase 3
10A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]CompletedNCT01280721Phase 3
11Effects of Somatostatin on Liver in ADPKDCompletedNCT02119052Phase 2, Phase 3
12Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT02225860Phase 2, Phase 3
13Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up StudyCompletedNCT00309283Phase 3
14Open-Label Tolvaptan Study in Subjects With ADPKDCompletedNCT01214421Phase 3
15Effects of Somatostatin on ADPKD HeartCompletedNCT02119013Phase 2, Phase 3
16Tolvaptan Phase 3 Efficacy and Safety Study in ADPKDCompletedNCT00428948Phase 3
17Lanreotide as Treatment of Polycystic LiversCompletedNCT00565097Phase 2, Phase 3
18Efficacy and Safety of Tolvaptan in Cirrhotic Patients With HyponatremiaCompletedNCT01850940Phase 3
19HALT Progression of Polycystic Kidney Disease (HALT PKD) Study BCompletedNCT01885559Phase 3
20HALT Progression of Polycystic Kidney Disease (HALT PKD) Study ACompletedNCT00283686Phase 3
21Octreotide in Severe Polycystic Liver DiseaseCompletedNCT00426153Phase 2, Phase 3
22Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)RecruitingNCT02964273Phase 3
23The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted RecipientsRecruitingNCT02134899Phase 3
24Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney DiseaseRecruitingNCT02055079Phase 3
25Lanreotide In Polycystic Kidney Disease StudyRecruitingNCT02127437Phase 3
26Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney DiseaseActive, not recruitingNCT02160145Phase 3
27Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal InsufficiencyActive, not recruitingNCT01377246Phase 3
28Study of Lanreotide to Treat Polycystic Kidney DiseaseActive, not recruitingNCT01616927Phase 3
29Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney DiseaseEnrolling by invitationNCT02251275Phase 3
30Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal InsufficiencyTerminatedNCT01223755Phase 2, Phase 3
31Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to TherapyTerminatedNCT00920309Phase 2, Phase 3
32Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)Unknown statusNCT00890279Phase 2
33Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression ControlUnknown statusNCT01932450Phase 2
34Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pain StudyUnknown statusNCT00571909Phase 2
35Bosutinib For Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT01233869Phase 2
368-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT01451827Phase 2
37A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]CompletedNCT00841568Phase 2
38Short-Term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT01336972Phase 2
39Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00286156Phase 1, Phase 2
40Effect of the Aquaretic Tolvaptan on Nitric Oxide SystemCompletedNCT02527863Phase 2
41Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKDCompletedNCT01210560Phase 2
42Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and SafetyCompletedNCT00491517Phase 2
43Tolvaptan Open-Label Pilot Efficacy, Tolerability and Safety Study in ADPKDCompletedNCT00413777Phase 2
44Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney DiseaseCompletedNCT02140814Phase 2
45Ursodeoxycholic Acid as Treatment for Polycystic Liver DiseaseCompletedNCT02021110Phase 2
46Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney DiseaseRecruitingNCT02656017Phase 2
47Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney DiseaseRecruitingNCT02697617Phase 2
48Feasibility Study of Metformin Therapy in ADPKDRecruitingNCT02903511Phase 2
49A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)Active, not recruitingNCT01559363Phase 1, Phase 2
50Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101Active, not recruitingNCT02616055Phase 2

Search NIH Clinical Center for Autosomal Dominant Polycystic Kidney Disease


Cochrane evidence based reviews: polycystic kidney diseases

Genetic Tests for Autosomal Dominant Polycystic Kidney Disease

About this section

Genetic tests related to Autosomal Dominant Polycystic Kidney Disease:

id Genetic test Affiliating Genes
1 Polycystic Kidney Disease, Adult Type27
2 Polycystic Kidney Disease, Autosomal Dominant27 24 PKD2

Anatomical Context for Autosomal Dominant Polycystic Kidney Disease

About this section

MalaCards organs/tissues related to Autosomal Dominant Polycystic Kidney Disease:

36
Kidney, Liver, Heart, Brain, Pancreas, Endothelial, Testes

FMA organs/tissues related to Autosomal Dominant Polycystic Kidney Disease:

17
The kidney

Publications for Autosomal Dominant Polycystic Kidney Disease

About this section

Articles related to Autosomal Dominant Polycystic Kidney Disease:

(show top 50)    (show all 620)
idTitleAuthorsYear
1
Acute aortic syndrome in autosomal dominant polycystic kidney disease. (28087011)
2017
2
Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease. (28532709)
2017
3
Genetics and Autosomal Dominant Polycystic Kidney Disease Progression. (28535524)
2017
4
Total kidney and liver volume is a major risk factor for malnutrition in ambulatory patients with autosomal dominant polycystic kidney disease. (28088190)
2017
5
Genetic analysis of Iranian autosomal dominant polycystic kidney disease: new insight to haplotype analysis. (26950445)
2016
6
Peritoneal dialysis for autosomal dominant polycystic kidney disease: a retrospective study. (27143265)
2016
7
Rare co-occurrence of osteogenesis imperfecta type I and autosomal dominant polycystic kidney disease. (27059743)
2016
8
Autophagy activators suppress cystogenesis in an autosomal dominant polycystic kidney disease model. (28007903)
2016
9
Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial. (27920153)
2016
10
Hyperaldosteronism and cardiovascular risk in patients with autosomal dominant polycystic kidney disease. (27442639)
2016
11
Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study. (27995519)
2016
12
Novel association of familial testicular germ cell tumor and autosomal dominant polycystic kidney disease with PKD1 mutation. (27577987)
2016
13
Frequency of Nerve Root Sleeve Cysts in Autosomal Dominant Polycystic Kidney Disease. (27994919)
2016
14
Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease. (27548646)
2016
15
Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease. (27578560)
2016
16
Re: Live Donor Renal Transplant with Simultaneous Bilateral Nephrectomy for Autosomal Dominant Polycystic Kidney Disease is Feasible and Satisfactory at Long-Term Follow-up. (27628816)
2016
17
Large hemorrhagic ovarian cyst in postmenopausal patient with autosomal dominant polycystic kidney disease. (27795640)
2016
18
The Risk for New-Onset Diabetes Mellitus after Kidney Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Meta-Analysis. (27184299)
2016
19
An association between autosomal-dominant polycystic kidney disease and the risk of acute myocardial infarction in Asian population - results of a nationwide study. (28038444)
2016
20
Low-Osmolar Diet and Adjusted Water Intake for Vasopressin Reduction in Autosomal Dominant Polycystic Kidney Disease: AA Pilot Randomized Controlled Trial. (27663039)
2016
21
Screening for Unruptured Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease: A Survey of 420 Nephrologists. (27054719)
2016
22
Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis. (26923419)
2016
23
Autosomal dominant polycystic kidney disease: recent advances in clinical management. (27594986)
2016
24
Performance of the CKD-EPI Equation to Estimate GFR in a Longitudinal Study of Autosomal Dominant Polycystic Kidney Disease. (28027795)
2016
25
Case report of renal pelvis squamous cell carcinoma with tumor embolus in autosomal dominant polycystic kidney disease. (27537592)
2016
26
Fatty Acid Oxidation is Impaired in An Orthologous Mouse Model of Autosomal Dominant Polycystic Kidney Disease. (27077126)
2016
27
Glioma in patients with autosomal dominant polycystic kidney disease. (27565461)
2016
28
Vascular endothelial growth factor as an angiogenesis biomarker for the progression of autosomal dominant polycystic kidney disease. (26909926)
2016
29
Pleuritic chest pain from portal hypertensive gastropathy in ESRD patient with autosomal dominant polycystic kidney disease misdiagnosed as pericarditis. (27069969)
2016
30
Recent advances in autosomal-dominant polycystic kidney disease. (27553994)
2016
31
Health-related quality of life across all stages of autosomal dominant polycystic kidney disease. (27662885)
2016
32
Whole-genome sequencing overcomes pseudogene homology to diagnose autosomal dominant polycystic kidney disease. (27165007)
2016
33
Toll-Like Receptors in the Progression of Autosomal Dominant Polycystic Kidney Disease. (27928906)
2016
34
Carbohydrate antigen 19-9 is significantly elevated in autosomal dominant polycystic kidney disease. (28024168)
2016
35
Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease. (26932689)
2016
36
Autosomal dominant polycystic kidney disease diagnosed in utero. Review. (27629138)
2016
37
The Clinical Manifestation and Management of Autosomal Dominant Polycystic Kidney Disease in China. (27921038)
2016
38
Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease. (27190355)
2016
39
Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease. (27650472)
2016
40
Renal volume and cardiovascular risk assessment in normotensive autosomal dominant polycystic kidney disease patients. (27930582)
2016
41
Comprehensive PKD1 and PKD2 Mutation Analysis in Prenatal Autosomal Dominant Polycystic Kidney Disease. (26139440)
2016
42
Fatal liver cyst rupture in polycystic liver disease complicated with autosomal dominant polycystic kidney disease: A case report. (27050907)
2016
43
Health-Related Quality Of Life (Hrqol) Measures In Autosomal Dominant Polycystic Kidney Disease (Adpkd). (26532872)
2015
44
Increased urinary Angiotensinogen/Creatinine (AGT/Cr) ratio may be associated with reduced renal function in autosomal dominant polycystic kidney disease patients. (26092580)
2015
45
Decade in review-polycystic kidney disease: Slowing progression of autosomal dominant polycystic kidney disease. (26460355)
2015
46
Cyst infection in autosomal dominant polycystic kidney disease: causative microorganisms and susceptibility to lipid-soluble antibiotics. (25851811)
2015
47
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. (25786098)
2015
48
Endovascular Treatment of Intracranial Aneurysms in Patients With Autosomal Dominant Polycystic Kidney Disease. (26492429)
2015
49
Autosomal dominant polycystic kidney disease: identification of two polymorphisms. (25847740)
2015
50
Opposing Effects of Inhibitors of Aurora-A and EGFR in Autosomal-Dominant Polycystic Kidney Disease. (26528438)
2015

Variations for Autosomal Dominant Polycystic Kidney Disease

About this section

Expression for genes affiliated with Autosomal Dominant Polycystic Kidney Disease

About this section
Search GEO for disease gene expression data for Autosomal Dominant Polycystic Kidney Disease.

Pathways for genes affiliated with Autosomal Dominant Polycystic Kidney Disease

About this section

Pathways related to Autosomal Dominant Polycystic Kidney Disease according to GeneCards Suite gene sharing:

(show all 23)
idSuper pathwaysScoreTop Affiliating Genes
19.9CFTR, NOS3
29.8MTOR, TSC1, TSC2
39.8MTOR, TSC1, TSC2
4
Show member pathways
9.8MTOR, TSC1, TSC2
59.7MTOR, NOS3, TSC2
69.7NOS3, TSC1, TSC2
7
Show member pathways
9.7ACE, NOS3, REN
89.6EGF, MTOR, NOS3
9
Show member pathways
9.6CFTR, MTOR, TSC1, TSC2
109.5EGF, MTOR, MYC
119.5EGF, MTOR, MYC
12
Show member pathways
9.5EGF, MTOR, TSC1, TSC2
13
Show member pathways
9.4MTOR, MYC, TSC1, TSC2
14
Show member pathways
9.4MTOR, MYC, TSC1, TSC2
159.4MTOR, MYC, TSC1, TSC2
169.4MTOR, MYC, TSC1, TSC2
179.4MTOR, MYC, TSC1, TSC2
18
Show member pathways
9.3EGF, MTOR, MYC, TSC2
19
Show member pathways
9.2CFTR, MTOR, NOS3, TSC1, TSC2
209.2CFTR, EGF, MYC, PCSK2
219.1EGF, MTOR, MYC, TSC1, TSC2
22
Show member pathways
8.8ACE, EGF, MTOR, PRKD1, REN, TSC1
238.7EGF, MTOR, MYC, NOS3, TSC1, TSC2

GO Terms for genes affiliated with Autosomal Dominant Polycystic Kidney Disease

About this section

Cellular components related to Autosomal Dominant Polycystic Kidney Disease according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1ciliary membraneGO:006017010.5PKD1, PKD2, PKD2L1
2basolateral plasma membraneGO:001632310.4AQP2, CFTR, ENPP1, PKD1
3polycystin complexGO:000213310.1PKD1, PKD2
4TSC1-TSC2 complexGO:003359610.0TSC1, TSC2
5plasma membraneGO:00058867.3ACE, AQP2, CFTR, EGF, ENPP1, NOS3
6membraneGO:00160206.8ACE, AQP2, CFTR, EGF, ENPP1, MTOR

Biological processes related to Autosomal Dominant Polycystic Kidney Disease according to GeneCards Suite gene sharing:

(show all 28)
idNameGO IDScoreTop Affiliating Genes
1cytoplasmic sequestering of transcription factorGO:004299410.8PKD1, PKD2
2anoikisGO:004327610.8MTOR, TSC2
3mesonephric duct developmentGO:007217710.7PKD1, PKD2
4mesonephric tubule developmentGO:007216410.7PKD1, PKD2
5metanephric ascending thin limb developmentGO:007221810.7PKD1, PKD2
6angiotensin maturationGO:000200310.7ACE, REN
7beta-amyloid metabolic processGO:005043510.7ACE, REN
8placenta blood vessel developmentGO:006067410.7PKD1, PKD2
9positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycleGO:003165910.7PKD1, PKD2
10metanephric collecting duct developmentGO:007220510.7AQP2, PKD1
11cellular response to hydrostatic pressureGO:007146410.6MYC, PKD2
12negative regulation of cell sizeGO:004579210.6MTOR, TSC1
13negative regulation of macroautophagyGO:001624210.5MTOR, TSC1
14energy reserve metabolic processGO:000611210.5MTOR, MYC
15regulation of calcium ion importGO:009027910.5EGF, PKD2
16positive regulation of glial cell proliferationGO:006025210.4MTOR, MYC
17negative regulation of glucose importGO:004632510.4ENPP1, MYC
18response to fluid shear stressGO:003440510.4NOS3, PKD1
19negative regulation of insulin receptor signaling pathwayGO:004662710.3ENPP1, TSC1, TSC2
20liver developmentGO:000188910.3PKD1, PKD2, PRKCSH
21regulation of blood pressureGO:000821710.2ACE, NOS3, REN
22membrane organizationGO:006102410.1CFTR, EGF, TSC1, TSC2
23renal system developmentGO:007200110.0PKD1, PKD2, PRKCSH
24calcium ion transmembrane transportGO:007058810.0PKD1, PKD2, PKD2L1, PKDREJ
25detection of mechanical stimulusGO:005098210.0PKD1, PKD2, PKD2L1, PKDREJ
26spinal cord developmentGO:00215109.9MTOR, PKD1, PKD2
27kidney developmentGO:00018229.8ACE, PKD1, PKD2, PKHD1, REN, TSC1
28cell cycle arrestGO:00070509.7MTOR, MYC, PKD1, PKD2, TSC1, TSC2

Molecular functions related to Autosomal Dominant Polycystic Kidney Disease according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1calcium channel activityGO:000526210.0PKD1, PKD2, PKD2L1, PKDREJ
2phosphoprotein bindingGO:00512199.6MTOR, PKD2, PRKCSH
3calcium ion bindingGO:00055098.8EGF, ENPP1, PKD2, PKD2L1, PKDREJ, PRKCSH

Sources for Autosomal Dominant Polycystic Kidney Disease

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet